Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations.
Journal
Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
13
10
2022
revised:
02
02
2023
accepted:
17
05
2023
medline:
30
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Resistance to immune checkpoint blockade remains challenging in patients with non-small cell lung cancer (NSCLC). Tumor-infiltrating leukocyte (TIL) quantity, composition, and activation status profoundly influence responsiveness to cancer immunotherapy. This study examined the immune landscape in the NSCLC tumor microenvironment by analyzing TIL profiles of 281 fresh resected NSCLC tissues. Unsupervised clustering based on numbers and percentages of 30 TIL types classified adenocarcinoma (LUAD) and squamous cell carcinoma (LUSQ) into the cold, myeloid cell-dominant, and CD8 The precise TIL profiling classified NSCLC into novel three immune subtypes that correlates with patient outcome, identifying subtype-specific molecular pathways and genomic alterations that should play important roles in constructing subtype-specific immune tumor microenvironments. These classifications of NSCLC based on TIL status are useful for developing personalized immune therapies for NSCLC.
Identifiants
pubmed: 37377611
doi: 10.1158/2767-9764.CRC-22-0415
pii: CRC-22-0415
pmc: PMC10263066
doi:
Substances chimiques
Protein-Tyrosine Kinases
EC 2.7.10.1
Proto-Oncogene Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1026-1040Informations de copyright
© 2023 The Authors; Published by the American Association for Cancer Research.
Références
Genome Biol. 2019 Oct 21;20(1):213
pubmed: 31639029
Clin Sci (Lond). 2021 Jan 15;135(1):35-52
pubmed: 33399850
Cell Metab. 2018 Jul 03;28(1):87-103.e6
pubmed: 29805099
EMBO Rep. 2022 Apr 5;23(4):e52984
pubmed: 35107856
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cells. 2021 Nov 11;10(11):
pubmed: 34831355
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Clin Cancer Res. 2010 Oct 1;16(19):4864-75
pubmed: 20643781
Cell Death Dis. 2017 May 11;8(5):e2779
pubmed: 28492541
Cell. 2020 Jul 9;182(1):200-225.e35
pubmed: 32649874
Mol Cancer. 2021 Feb 5;20(1):28
pubmed: 33546704
Nat Commun. 2017 Feb 01;8:14381
pubmed: 28146145
Hum Immunol. 2004 Nov;65(11):1377-88
pubmed: 15556688
Nat Biotechnol. 2018 Sep;36(8):758-764
pubmed: 30010674
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
Cancer Cell. 2021 Jun 14;39(6):845-865.e7
pubmed: 34019806
World J Clin Oncol. 2021 Apr 24;12(4):217-237
pubmed: 33959476
J Clin Oncol. 2006 Nov 1;24(31):5079-90
pubmed: 17075127
Sci Adv. 2021 Feb 3;7(6):
pubmed: 33536206
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Sci Rep. 2018 Oct 1;8(1):14576
pubmed: 30275546
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Cancer Cell. 2019 Apr 15;35(4):559-572.e7
pubmed: 30905761
Nat Rev Cancer. 2019 Sep;19(9):495-509
pubmed: 31406302
Immunity. 2020 Jul 14;53(1):187-203.e8
pubmed: 32640259
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873
pubmed: 27100738
Mol Ther Oncolytics. 2020 Apr 07;17:241-249
pubmed: 32346613
BMC Cancer. 2018 Dec 5;18(1):1220
pubmed: 30518340
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Cancer Res. 2009 Jun 1;69(11):4918-25
pubmed: 19458066
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Cell Rep. 2017 Jan 3;18(1):248-262
pubmed: 28052254
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
J Clin Oncol. 2014 Aug 1;32(22):2357-64
pubmed: 24799473
FEBS Open Bio. 2020 Sep;10(9):1921-1933
pubmed: 32686362
Immunity. 2018 Mar 20;48(3):399-416
pubmed: 29562192
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
J Thorac Oncol. 2017 May;12(5):791-803
pubmed: 28088513
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Biomolecules. 2020 Apr 25;10(5):
pubmed: 32344837
Front Immunol. 2018 Feb 27;9:367
pubmed: 29535734